Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator

Molecular Pharmacology

Volumn 80, Issue 1, 2011, Pages 163-173

  Smith, Nicola J ^a   Ward, Richard J ^a   Stoddart, Leigh A ^a   Hudson, Brian D ^a   Kostenis, Evi ^b   Ulven, Trond ^c   Morris, Joanne C ^d   Tränkle, Christian ^b   Tikhonova, Irina G ^e   Adams, David R ^d   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d HERIOT WATT UNIVERSITY   (United Kingdom)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLORO ALPHA (1 METHYLETHYL) N 2 THIAZOLYLBENZENEACETAMIDE; ACETANILIDE; FREE FATTY ACID RECEPTOR 2; FREE FATTY ACID RECEPTOR 3; G PROTEIN COUPLED RECEPTOR; LEUCINE; PARTIAL AGONIST; UNCLASSIFIED DRUG;

ALLOSTERISM; AMINO ACID SUBSTITUTION; ARTICLE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HYDROGEN BOND; ISOMERISM; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ACETAMIDES; ALLOSTERIC REGULATION; CELLS, CULTURED; FATTY ACIDS; HUMANS; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, CELL SURFACE;

EID: 79959309348     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.070789     Document Type: Article

References (41)

1. Ahn KH, Bertalovitz AC, Mierke DF, and Kendall DA (2009) Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization. Mol Pharmacol 76:833-842.
2. Alexander SP, Mathie A, and Peters JA (2008) Guide to receptors and channels (GRAC), 3rd ed. Br J Pharmacol 153 (Suppl. 2):S1-S209.
3. Antony J, Kellershohn K, Mohr-Andrä M, Kebig A, Prilla S, Muth M, Heller E, Disingrini T, Dallanoce C, Bertoni S, et al. (2009) Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 23:442-450.
4. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25:366-428.
5. Banères JL, Mesnier D, Martin A, Joubert L, Dumuis A, and Bockaert J (2005) Molecular characterization of a purified 5-HT4 receptor: a structural basis for drug efficacy. J Biol Chem 280:20253-20260. (Pubitemid 40776722)
6. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, Rosenbaum DM, Fung JJ, Choi HJ, Thian FS, Kobilka TS, et al. (2010) Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463:108-112.
7. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, et al. (2003) The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278:11312-11319. (Pubitemid 36792688)
8. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
9. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374. (Pubitemid 34575719)
10. Conn PJ, Jones CK, and Lindsley CW (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 30:148-155.
11. Conner M, Hawtin SR, Simms J, Wootten D, Lawson Z, Conner AC, Parslow RA, and Wheatley M (2007) Systematic analysis of the entire second extracellular loop of the V(1a) vasopressin receptor: key residues, conserved throughout a G-protein-coupled receptor family, identified. J Biol Chem 282:17405-17412. (Pubitemid 47100317)
12. Eglen RM (2005) Muscarinic receptor subtype pharmacology and physiology. Prog Med Chem 43:105-136.
13. Huber T, Menon S, and Sakmar TP (2008) Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery. Biochemistry 47:11013-11023.
14. Jadhav PK, Ala P, Woerner FJ, Chang CH, Garber SS, Anton ED, and Bacheler LT (1997) Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J Med Chem 40:181-191. (Pubitemid 27045074)
15. Kamata K, Mitsuya M, Nishimura T, Eiki J, and Nagata Y (2004) Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12:429-438. (Pubitemid 38353064)
16. Kenakin TP (2009) '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30:460-469.
17. Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60:24-35.
18. Kimura M, Mizukami Y, Miura T, Fujimoto K, Kobayashi S, and Matsuzaki M (2001) Orphan G protein-coupled receptor, GPR41, induces apoptosis via a p53/Bax pathway during ischemic hypoxia and reoxygenation. J Biol Chem 276:26453-26460.
19. Kotarsky K, Nilsson NE, Olde B, and Owman C (2003) Progress in methodology. Improved reporter gene assays used to identify ligands acting on orphan seventransmembrane receptors. Pharmacol Toxicol 93:249-258.
20. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, Brezillon S, Dupriez V, Vassart G, Van Damme J, et al. (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278:25481-25489. (Pubitemid 36835299)
21. Lee T, Schwandner R, Swaminath G, Weiszmann J, Cardozo M, Greenberg J, Jaeckel P, Ge H, Wang Y, Jiao X, et al. (2008) Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol Pharmacol 74:1599-1609.
22. Liu C, Wu J, Zhu J, Kuei C, Yu J, Shelton J, Sutton SW, Li X, Yun SJ, Mirzadegan T, et al. (2009) Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J Biol Chem 284:2811-2822.
23. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, et al. (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461:1282-1286.
24. Milligan G, Stoddart LA, and Smith NJ (2009) Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br J Pharmacol 158:146-153.
25. Nawaratne V, Leach K, Felder CC, Sexton PM, and Christopoulos A (2010) Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J Biol Chem 285:19012-19021.
26. Nilsson NE, Kotarsky K, Owman C, and Olde B (2003) Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun 303:1047-1052. (Pubitemid 36390250)
27. Peeters MC, van Westen GJ, Li Q, and Ijzerman AP (2011) Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol Sci 32:35-42.
28. Scarselli M, Li B, Kim SK, and Wess J (2007) Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation. J Biol Chem 282:7385-7396. (Pubitemid 47093690)
29. Sina C, Gavrilova O, Förster M, Till A, Derer S, Hildebrand F, Raabe B, Chalaris A, Scheller J, Rehmann A, et al. (2009) G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol 183:7514-7522.
30. Sleeth ML, Thompson EL, Ford HE, Zac-Varghese SE, and Frost G (2010) Free fatty acid receptor 2 and nutrient sensing: a proposed role for fibre, fermentable carbohydrates and short-chain fatty acids in appetite regulation. Nutr Res Rev 23:135-145.
31. Smith NJ, Bennett KA, and Milligan G (2011) When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol 331:241-247.
32. Smith NJ and Milligan G (2010) Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev 62:701-725.
33. Smith NJ, Stoddart LA, Devine NM, Jenkins L, and Milligan G (2009) The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J Biol Chem 284:17527-17539.
34. Soudijn W, Van Wijngaarden I, and IJzerman AP (2004) Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. Drug Discov Today 9:752-758. (Pubitemid 39140802)
35. 35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol Pharmacol 71:994-1005.
36. Stoddart LA, Smith NJ, Jenkins L, Brown AJ, and Milligan G (2008a) Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J Biol Chem 283:32913-32924.
37. Stoddart LA, Smith NJ, and Milligan G (2008b) International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 60:405-417.
38. Sum CS, Tikhonova IG, Costanzi S, and Gershengorn MC (2009) Two arginineglutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. J Biol Chem 284:3529-3536.
39. Sum CS, Tikhonova IG, Neumann S, Engel S, Raaka BM, Costanzi S, and Gershengorn MC (2007) Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 282:29248-29255. (Pubitemid 350043382)
40. Unal H, Jagannathan R, Bhat MB, and Karnik SS (2010) Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J Biol Chem 285:16341-16350.
41. Wang Y, Jiao X, Kayser F, Liu J, Wang Z, Wanska M, Greenberg J, Weiszmann J, Ge H, Tian H, et al. (2010) The first synthetic agonists of FFA2: discovery and SAR of phenylacetamides as allosteric modulators. Bioorg Med Chem Lett 20:493-498.